EverGlade Insights Blog

A New Valley of Death? by Eric Jia-Sobota

It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic...

COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota

Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting...

New Opportunity for COVID Therapeutics by Eric Jia-Sobota

For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of...

ACC-JCRD seeking Commercial Solutions by Eric Jia-Sobota

The Joint Army Contracting Command and the Joint COVID Response Division (ACC-JCRD) recently published a solicitation seeking Commercial Solutions to decrease US reliance on fragile global supply chains and increase preparedness for future pandemics. The...

BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work

Executive Summary BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden...

DPA Funding Opportunity by Eric Jia-Sobota

The DPA Title III program just received an additional $10B in the recovery legislation that was recently passed. The DPA program is administered by the US Air Force and more information can be found here...